Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase | Zendy

Ling Xiao | Zendy; Joe-Élie Salem | Zendy; Sebastian Clauß | Zendy; Alan Hanley | Zendy; Aneesh Bapat | Zendy; Maarten Hulsmans | Zendy; Yoshiko Iwamoto | Zendy; Gregory R. Wojtkiewicz | Zendy; Murat Çetinbaş | Zendy; Maximilian J. Schloss | Zendy; Justin Tedeschi | Zendy; Bénédicte LebrunVignes | Zendy; Alicia Lundby | Zendy; Ruslan I. Sadreyev | Zendy; Javid J. Moslehi | Zendy; Matthias Nahrendorf | Zendy; Patrick T. Ellinor | Zendy; David J. Milan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Author(s) -

Ling Xiao,

Joe-Élie Salem,

Sebastian Clauß,

Alan Hanley,

Aneesh Bapat,

Maarten Hulsmans,

Yoshiko Iwamoto,

Gregory R. Wojtkiewicz,

Murat Çetinbaş,

Maximilian J. Schloss,

Justin Tedeschi,

Bénédicte LebrunVignes,

Alicia Lundby,

Ruslan I. Sadreyev,

Javid J. Moslehi,

Matthias Nahrendorf,

Patrick T. Ellinor,

David J. Milan

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.049210

Subject(s) - ibrutinib , medicine , bruton's tyrosine kinase , tyrosine kinase , pharmacology , proto oncogene tyrosine protein kinase src , atrial fibrillation , tyrosine kinase inhibitor , cancer research , receptor , leukemia , cancer , chronic lymphocytic leukemia

Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research